Vol 12, No 2: June 2015 (Special Issue on Immunotherapy for Lung Cancer)

Table of Contents

Editorial

PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors PDF HTML
Rafael Rosell, Ramón Palmero 71-73
Tumor immune microenvironment characterization and response to anti-PD-1 therapy PDF HTML
Mariacarmela Santarpia, Niki Karachaliou 74-78

Review

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints PDF HTML
Niki Karachaliou, Maria Gonzalez Cao, Cristina Teixidó, Santiago Viteri, Daniela Morales-Espinosa, Mariacarmela Santarpia, Rafael Rosell 79-86
Assays for predicting and monitoring responses to lung cancer immunotherapy PDF HTML
Cristina Teixidó, Niki Karachaliou, Maria González-Cao, Daniela Morales-Espinosa, Rafael Rosell 87-95

Original Article

Changes in tumor-antigen expression profile as human small-cell lung cancers progress PDF HTML
Li-Sheng Ge, Neil T. Hoa, Nils Lambrecht, Maria Dacosta-Iyer, Yi Ouyang, Amir Abolhoda, Martin R. Jadus 96-105

Review

Current approaches in treatment of triple-negative breast cancer PDF HTML
Hanan Ahmed Wahba, Hend Ahmed El-Hadaad 106-116

Original Article

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposidecarboplatin/ cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases PDF HTML
Yue-Ya Li, Chan Zhou, Deng-Xia Yang, Jing Wang, Zhu-Jun Liu, Xin-Yue Wang, Kai Li 117-125
Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis PDF HTML
Jie-Ying Chen, Ya-Nan Cheng, Lei Han, Feng Wei, Wen-Wen Yu, Xin-Wei Zhang, Shui Cao, Jin-Pu Yu 126-139


OUR FRIENDS